• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: Biosimilars to revolutionize global drug development, 700 therapies in pipelines

Report: Biosimilars to revolutionize global drug development, 700 therapies in pipelines

October 1, 2014
CenterWatch Staff

There currently are 700 follow-on biologics therapies moving through pipelines, with many already approved, and 245 biopharma companies and institutes developing or already marketing follow-on biologics in markets throughout the world, according to Thomson Reuters.

According to a newly released Thomas Reuters report, Biosimilars: A Global Perspective of a New Market—Opportunities, Threats and Critical Strategies 2014, biosimilars are expected to account for approximately one quarter of the $100 billion of sales stemming from off-patent biologics by the end of the decade.

South Korea is a notable standout in the race for global leadership in this space, and India anticipates biosimilars becoming the most important economic and therapeutic component of its already robust biopharma industry.

The report found big pharma and generics makers face a steep learning curve. While generic makers currently lead the pack, the expertise in this market is held by the biologics makers. New pure-play biosimilar makers funded by governments and private investors also have a strong presence in this arena.

Typically offering 20% to 30% discounts from innovator biologics, biosimilars are expected to deliver $11 billion to $33 billion in savings across the European Union by 2020. Slow market uptake of biosimilars in the E.U. may not also hold true for the U.S. Unlike most of the E.U., the U.S. will allow interchangeability, which is expected to speed adoption and lead to lower prices.

Startups working to make and sell biosimilars in emerging territories could be the “David” ticket to beat pharma “Goliaths” that dominate those realms, according to the report. The World Health Organization recently proposed a voluntary, global naming scheme that could level the playing field for biosimilars and their reference biologics.

In many parts of the world, follow-ons offer new hope to patients who previously did not have access to pricey biologics, bringing the power of biologics for the first time to markets in Africa, Asia, Eastern Europe and Latin America.

“Rather than forgo the benefits of biologics, governments and payers are counting on biosimilars to dramatically change drug development and patient costs by reducing the price tag of important biologics and increasing access to life-saving drugs,” said Jon Brett-Harris, managing director of Thomson Reuters Life Sciences. “For this to happen, biosimilars must deliver the power of the reference drugs at a price developing countries can afford and gain the confidence of the marketplace. They have to create their own market.”

Upcoming Events

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • MachineLearning-360x240.png

    Industry Using AI/ML to Improve Data, Quality and Trial Management, Survey Says

  • VirtualTraining-360x240.png

    Virtual Training Evolves into More In-Depth Learning, Improved Communications

  • SurveywBlueBackground-360x240.png

    Mid-Study Updates Delay Trials At Least a Month, CSDD Report Finds

  • Real-TimeData-360x240.png

    Real-Time Data Helped Sponsors Respond to Sites’ Needs During the Pandemic

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing